Switching from Originator Infliximab* to Biosimilar CT-P13 Compared with Maintained Treatment with Originator Infliximab in patients with Spondyloarthritis

Switching from Originator Infliximab to Biosimilar CT-P13 Compared with Maintained Treatment with Originator Infliximab

Direct Comparison of Originator Infliximab to Biosimilar CT-P13 in Ankylosing Spondylitis

One-Year Retention of Treatment with Biosimilar CT-P13 Compared to Originator Infliximab

Direct Comparison of Originator Etanercept to Biosimilar GP2015 in Psoriasis

ASAS20 and ASAS40 Response to Ixekizumab at Week 16 in Patients with Radiographic Axial Spondyloarthritis

ASAS40 Response to Ixekizumab at Week 16 in Anti-TNF Naïve Patients and in Anti-TNF Inadequate Responders with Radiographic Axial Spondyloarthritis

ASAS40 Response to Ixekizumab through 52 weeks in Patients with Radiographic Axial Spondyloarthritis (r-axSpA)

ASAS40 Response to Ixekizumab at Week 16 in Patients with Non Radiographic Axial Spondyloarthritis (nr-axSpA)

Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis Receiving Ixekizumab Over 2 Years

Auto Draft

ASAS40 Response to Bimekizumab until Week 24 in Patients with Non-radiographic and Radiographic Axial Spondyloarthritis

ASAS40 Response in Patients with Axial Spondyloarthritis Treated with tsDMARDs

ASAS40 Response to Upadacitinib at Week 14 in Patients with Non-radiographic Axial Spondyloarthritis